US 2020/0369772 A1 · ANTI-HUMAN PD-L2 ANTIBODIES

An anti-human PD-L2 antibody or the antigen binding part thereof, which specifically binds human PD-L2 such that PD-L2 binding to PD-1 is blocked,

wherein the antibody, or antigen binding part thereof, comprises six CDR sequences comprised in the heavy chain variable regions and light chain variable regions, respectively, as defined in any of the below items a) to q), or
wherein the antibody, or antigen binding part thereof, comprises six CDR sequences comprised in the heavy chain variable regions and light chain variable regions, respectively, as defined in any of the below items a) to q), wherein up to 1,2,3 amino acid residues in the CDR sequences are substituted:
a) a heavy chain variable region which has the sequence of SEQ ID NO:
2 and a light chain variable region which has the sequence of SEQ ID NO:
10;
b) a heavy chain variable region which has the sequence of SEQ ID NO:
18 and a light chain variable region which has the sequence of SEQ ID NO:
26;
c) a heavy chain variable region which has the sequence of SEQ ID NO:
34 and a light chain variable region which has the sequence of SEQ ID NO:
42;
d) a heavy chain variable region which has the sequence of SEQ ID NO:
50 and a light chain variable region which has the sequence of SEQ ID NO:
58;
e) a heavy chain variable region which has the sequence of SEQ ID NO:
50 and a light chain variable region which has the sequence of SEQ ID NO:
66;
f) a heavy chain variable region which has the sequence of SEQ ID NO:
96 and a light chain variable region which has the sequence of SEQ ID NO:
104;
g) a heavy chain variable region which has the sequence of SEQ ID NO:
112 and a light chain variable region which has the sequence of SEQ ID NO:
120;
h) a heavy chain variable region which has the sequence of SEQ ID NO:
128 and a light chain variable region which has the sequence of SEQ ID NO:
132;
i) a heavy chain variable region which has the sequence of SEQ ID NO:
140 and a light chain variable region which has the sequence of SEQ ID NO:
146;
j) a heavy chain variable region which has the sequence of SEQ ID NO:
152 and a light chain variable region which has the sequence of SEQ ID NO:
160;
k) a heavy chain variable region which has the sequence of SEQ ID NO:
166 and a light chain variable region which has the sequence of SEQ ID NO:
174;
l) a heavy chain variable region which has the sequence of SEQ ID NO:
96 and a light chain variable region which has the sequence of SEQ ID NO:
212;
m) a heavy chain variable region which has the sequence of SEQ ID NO:
140 and a light chain variable region which has the sequence of SEQ ID NO:
218;
n) a heavy chain variable region which has the sequence of SEQ ID NO:
220 and a light chain variable region which has the sequence of SEQ ID NO:
160;
o) a heavy chain variable region which has the sequence of SEQ ID NO:
220 and a light chain variable region which has the sequence of SEQ ID NO:
26;
p) a heavy chain variable region which has the sequence of SEQ ID NO:
220 and a light chain variable region which has the sequence of SEQ ID NO:
226;
or
q) a heavy chain variable region which has the sequence of SEQ ID NO:
220 and a light chain variable region which has the sequence of SEQ ID NO:
230.

51 more elements

The antibody or antigen binding part thereof, according to any one of the preceding claims, which antibody or antigen binding part fulfils at least one, preferably 2, 3 or 4 of the functional features listed in a) to d)

a) higher binding affinity to PD-L2 compared to the reference antibodies MIH18 and 24F.10C12;
b) more efficient blocking of PD-L2 binding to PD-1 compared to the reference antibodies MIH18 and 24F.10C12;
c) more efficient activation of TCR-mediated IL-2 expression compared to the reference antibodies MIH18 and 24F.10C12;
and
d) induction of higher IL-2 levels upon TCR-mediated IL-2 expression compared to the reference antibodies MIH18 and 24F.10C12.

2 more elements

The antibody or antigen binding part thereof, according to any one of the preceding claims, which is a humanized or a fully human antibody.

The antibody or antigen binding part according to any one of the preceding claims, which is of the IgG1, IgG2, IgG3 or IgG4 isotype.

The antibody or antigen binding part according to any one of the preceding claims, which is of the IgG1 isotype.

The antibody or antigen binding part according to any one of the preceding claims, wherein the antibody or antigen binding part is a monospecific, bispecific, trispecific or multispecific antibody or antigen binding part thereof.

The antibody or antigen binding part according to any one of the preceding claims, wherein the antibody or antigen binding part thereof blocks the binding to PD-L2 to another receptor than PD-1.

An antibody or antigen binding part thereof, which binds to the same epitope and/or competes for the same epitope with any of the antibodies or antigen binding parts of any of the preceding claims.

Anti-human pd-l2 antibodies

Life of this patent

Anti-human pd-l2 antibodies

Life of this patent

Abstract

Claims25